We aimed to report our stereotactic radiotherapy experience with Cyberknife (Accuray, Inc., Sunnyvale, CA, USA) for patients with recurrent high grade glial tumor. Forty-two patients with histologically proven malign glioma (30 glioblastoma, 12 anaplastic astrocytoma) and also treated with previous conventional fractioned radiotherapy underwent stereotactic radiotherapy via Cyberknife for their recurrent tumor in Ankara Oncology Hospital between July 2009-and September 2012. The median follow up time was 30 months (range, 8-144 months) after diagnosis and 10 months (range, 1-38 months) from stereotactic radiotherapy (SRT). The median survival from SRT are 8 months for glioblastoma patients and 11 months for grade 3 malign glioma patients (p= 0.157). The median survival from SRT are 9 months and 11 months in patients given chemotherapy and not given, respectively (p= 0.436). The median survival from SRT are 10 months in patients reoperated and 9 months not reoperated ( p= 0.827). Stereotactic radiotherapy is an effective treatment modality in patients with recurrent glial tumor.
INTRODUCTION
High grade gliomas account for approximately half of all primary brain tumors in adults. Glioblastoma multiforme (GBM) accounts for approximately 75% of all high grade gliomas. Standart treatment of patients with GBM is surgical resection followed by adjuvant radiotherapy. Maximal surgical resection followed by radiotherapy with concomitant and adjuvant temozolomide improved survival. 1, 2, 3, 4 But the prognosis for patient with GBM generally is poor and median survival time approximately one year.
Anaplastic gliomas constitute approximately 25% of high grade gliomas in adults. Anaplastic gliomas, comprising anaplastic astrocytomas, anaplastic oligodendrogliomas, and anaplastic mixed oligoastrocytomas, correspond to WHO (World Health Organization) grade 3. The patients with anaplastic astrocytoma have a median survival of approximately three years following diagnosis.
Several therapeutic options which consists of chemotherapy, palliative debulking surgery and repeated radiotherapy with stereotactic radiosurgery or stereotactic radiotherapy ( SRT) has been considered for patients with recurrent GBM. [5] [6] [7] [8] [9] [10] [11] [12] Stereotactic radiosurgery or SRT methods has been explored for treating recurrent glioma. 5, 7, 8, 13, 14, 15 Robotically guided radiosurgery system (Cyberknife, Accuray Inc,Sunnyvale, CA,USA) consists of 6 MV linear accelerator mounted on robot arm. 16 This system uses image guidance system and computer controlled robot to correct patient movement during treatment.The position of the robot is updated with real time radiographs taken during treatment. It use large number of beams (100-150 for cranial tumors) and provides local dose escalation on the targeted area without damaging surrounding normal tissue. Because of this advantages, it can be useful option for treatment of recurrent glial tumors.Therefore, we considered to review the effectiveness of stereotactic radiotherapy in the treatment of recurrent high grade glial tumor.
PATIENTS AND METHODS

Patients
We examined survival rates of 42 patients with high grade glial tumor who treated with CyberKnife stereotactic radiotherapy at the time of tumor recurrence or progression.The SRT were applied in single instituation, Ankara Oncology Education and Resourch Hospital between between July 2009 and September 2012. Table 1 shows clinical information of the all patients.Tumors in any location were considered for treatment. The median time from primer radiotherapy to recurrens was 15 months (min= 2, max= 104).The median time from primer radiotherapy to Cyberknife treatment was 19 months (min= 3, max= 106).
Operation methods were total resection in 18 patients, subtotal resection in 20 patients, biopsy only in 4 patients. All patients had received 60 Gy external beam radiotherapy as 2 Gy fractions 5 days per week . Twenty-three patients had also recevied adjuvant chemotherapy. Chemotherapy protocols were temozolomide in 21 patients ( concomitant daily 75 mg/m 2 /day with radiotherapy followed by six cycles adjuvan temozolomid 150-200 mg/m 2 / day) , PVC (Procarbazine, Vinciristine, Carmustine) in 1 patient and CCNU ( Lomustine) in 1 patient. Fourteen of 42 patients were reoperated at the time of recurrence before SRT.
Stereotactic Radiotherapy
The patients were informed about the potential risks and benefits of robotic fractioned stereotactic radiotherapy (FSRT) and their informed consents were obtained. Computed tomography scans with 1.5 mm slice intervals and magnetic resonans imaging (MRI) with 3 mm slice intervals were used for treatment planning. These two images were fused to better visualize tumor and critical structures. The radiation oncologist contoured the tumoral lesions and critical structures including optic nerves, International Journal of Hematology and Oncology brain stem, eyes and optic chiasma. Planning tumor volume (PTV) was defined with 1-2 mm margin from gross tumor volume ( GTV). A non-isocentric conformal planning with multipl beams (100-150 beams) and inverse planning methods was used to deliver high doses to target volume while minimizing dose to the critical structures. For treatment the patient was placed in the treatment position with the thermoplastic mask. Bony anatomy of the skull was used as a reference for tracking. X-ray images acquired in real time in treatment position. Digitally reconstructed radiograph (DRR ) was used as a reference. Differences of the skull positions between the DRR and the x-ray images were calculated and corrected. During treatment delivery, x-ray images were taken every 1-3 beams and the robot adjusted its' position to correct for any residual rotations and translations.
SRT treatment parameters are summarized in Table  2 .Treatment was delivered in 1-5 fractions (mean 3). Mean conformality index was 1.7 (1.04-2.4). Iris collimator was used in 24 patients (57%). The mean target volume was 42 ml (range, 3.60-144 ml).The mean prescribed dose was 18 Gy ( range, 12-30 Gy).
Follow-Up
Clinical and radiological response were evaluated every three months with MRI images.
Statistical Method
Overall survival were estimated with Kaplan-Meier method. Patient, tumor and treatment related variables were analyzed by univariate analysis.
RESULTS
Median follow-up time from diagnosis was 30 months (range, 8-144 months). Figure 1 shows overall survival of 42 patients. Median follow-up time from stereotactic radiotherapy (SRT) was 10 months (range, 1-38 months).
Median survival from diagnosis were 28 months for glioblastoma multiforme (GBM) patients and 41 months for patients with anaplastic glial tumors (p= 0.002) (Figure 2 ). Median survival after completion of SRT was 8 months for GBM patients and 11 months for grade 3 patients (p= 0.157). ( Figure  3 ).
Out of 42 patients, 23 received chemotherapy prior to SRT. The median survival after diagnosis were 28 months and 41 months for patients who received chemotherapy and who didn't receive, respectively (p= 0.002). Median survival after SRT were 9 months and 11 months for patients who received chemotherapy and didn't chemotherapy , respectively (p= 0.436).
The median survival starting from diagnosis were 26 months for patients with gross tumor volume ≤10 ml and 32 months for patients with tumor volume >10 ml (p= 0.265 ). The median survival after completion SRT were 9 months for patients with gross tumor volume ≤10 ml and 10 months for patients gross tumor volume >10 ml (p= 0.983). Although stereotactic radiosurgery is generally preferred for lesions smaller than 10 ml in diameter,in this study most of the these patients (90.9%) received FSRT. So we are able to compare results of these two groups (≤10 ml lesions vs >10 ml). The median survival after initial diagnosis were 30 months for patients reoperated at the time of recurrence and 29 months for patients who were not reoperated (p= 0.239). The median survival after SRT were 10 months for patients reoperated and 9 months for patients who were not reoperated (p= 0.827).
Complications: Vision impairment secondary to brain necrosis was seen in two patients.Asymptomatic brain necrosis was seen in four patients which was corrected with magnetic resonance spectroscopy.
DISCUSSION
Stereotactic radiosurgery and radiotherapy methods have been used so far fot the treatment of recurrent GBM and anaplastic glial tumors. 13, 14, 15 The Gammaknife (Elekta AB,Stockholm, Sweden) system uses Cobalt 60 radiation source. This system requires invasive immmobilization methods to prevent patient immobilization. Robotically guided stereotactic radiotherapy and radiosurgery system (Cyberknife, Accuray Inc, Sunnyvale, CA,USA) does not require invasive immobilization methods. It uses image guidance system and computer controlled robot to correct patient movement during treatment. So, brain treatment with Cyberknife system is completely noninvasive method of delivering stereotactic radiosurgery and radiotherapy.
In this study, we examined survival outcomes of stereotactic radiotherapy in the recurrent high grade glioma patients treated in our center.
Survival following stereotactic radiosurgery for GBM with Gammaknife has been explored. 5, 6, [17] [18] [19] [20] Pouration N. et al reported retrospectively the treatment results of 48 patients with pathologically proven GBM .Patients treated at the time of progression had significantly longer overall survival than those treated on initial presentation (17.4 vs 15.1 months. p= 0.003). On multivariate analysis, patients with more extensive resections had significantly better survival. 5 There are limited studies about glial tumor treatment with CyberKnife, stereotactic radiotherapy because of short history of this system. 7, 8, 13, 14, 15, 21, 22 Alan T. Villavicencio et al. reported survival after stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme with a multicenter experience. 8 In this study, twenty patients underwent CyberKnife treatment at the time of initial diagnosis, twenty-six patients were treated at the time of tumor recurrence or progression. The median survival from the diagnosis for the patients treated with CyberKnife as an initial clinical therapy was 11.5 months compared to 21 months fort the patients treated at the time of tumor recurrence or progression. This difference was statistically significant (p= 0.0004). The median survival from CyberKnife treatment was 9.5 months and 7 months for patients in the newly diagnosed and recurrent GBM groups (p= 0.79). They concluded that there is no appearent survival advantage of using CyberKnife for the initial management of GBM patients, and they suggest that it should be reserved for patients whose tumors recur or progress after conventional therapy. Clinical outcome were analyzed and compared with the historical control group who were treated at the same institution between 1995 and 1999. Compared with historic control group, stereotactic radiosurgery significantly prolonged survival as a salvage treatment in patients with recurrent glioblastomas (23 months vs 2 months, p< 0.001) , but it wasn't found to provide a significant survival benefit in patients with recurrent grade 3 gliomas (37.5 months vs 26 months; p= 0.789).
The prognosis of patients with GBM generally is poor and median survival time approximately is one year. In our study, the median survival from the diagnosis were 28 months for GBM patients and 41 months for grade 3 astrocytoma patients. Our results are similar with the other reports which are reported survival advantage of stereotactic radiotherapy for recurrent tumors. 8, 15 We saw survival advantage in patients treated with stereotactic radiotherapy at the time of tumor recurrence or progression (28 months). We agree that stereotactic radiotherapy should reserve at the time of tumor recurrence or progression after conventional radiotherapy.
Median survival of grade 3 astrocytoma patients is aproximately three years. In our study , the median survival from diagnosis was 41 months for grade 3 astrocytoma patients and there's a significant survival advantage when compared to GBM patients (41 months versus 28 months, p= 0.002). On the other hand, the median survival of grade 3 astrocytoma patients after completion of SRT was similar with GBM patients (11 months versus 8 months, p= 0.157). It can be related that the mean recurrence time from diagnosis is longer than GBM patients (41 months versus 18 months).
In this study, 14 patients had salvage operation at the time of recurrence prior to SRT. The median survival from SRT is slightly better in these patients, but it wasn't statistically significant (10 months versus 9 months, p= 0.827).
There are some reports which represent survival advantage of temozolomide treatment especially in the glioblastoma multiforme patients. 1, 2, 3 On the contrary, in the current study we found the median survival is statistically better in patients without chemotherapy (41 months versus 28 months, p= 0.002). We assumed that, this could be related with the most of the patients (60%) who didn't receive chemotherapy had grade 3 astrocytoma.
CONCLUSION
Reirradiation is one of the treatment option for recurrent glial tumors. Stereotactic radiotherapy can be an effective treatment modality for recurrent high grade glial tumors. Although survival from diagnosis is better in anaplastic tumors, survival from stereotactic radiotherapy are similar in both anaplastic tumors and glioblastom.
